Product Pipeline

Developing drugs for drug-resistant, life threatening infections.

Product Candidates

The next generation of anti-infectives.

We intend to develop and commercialize novel, first-in-class biologic therapies, known as direct lytic agents (DLAs), to treat life-threatening infections, including those caused by drug-resistant pathogens. The increasing prevalence of antibiotic resistance among bacterial pathogens has been widely recognized as an urgent public health threat by the CDC, the WHO and the Infectious Disease Society of America.

Our lead lysin, exebacase (CF-301) is an investigational product candidate that targets Staph aureus, including MRSA strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. We have announced positive results from this first-in-patient Phase 2 superiority study of exebacase, which showed clinically meaningful improvement in clinical responder rates among patients treated with exebacase in addition to standard-of-care (“SOC”) antibiotics compared to SOC antibiotics alone. We have developed a novel, engineered variant of exebacase, CF-296, with potential as a targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections such as prosthetic joint infections. Our research efforts are focused on a broad-based Gram-negative discovery program which aims to identify, optimize and develop DLAs that target deadly Gram-negative pathogens. We have discovered and engineered lysins with potent activity against drug-resistant Pseudomonas aeruginosa (“P. aeruginosa”) bacteria, a major cause of morbidity and mortality in patients with hospital acquired pneumonia and a major medical challenge for patients with cystic fibrosis. We have also discovered a novel class of phage-derived DLAs, known as amurin peptides, which have displayed potent activity against a wide range of Gram-negative pathogens in preclinical studies, including deadly, drug-resistant P. aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Enterobacter cloacae bacteria species.

*Exebacase has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia.

Product Candidates

Market Need

Drug resistance is a global crisis

2 Million

Illnesses Diagnosed in the U.S.


Deaths, Worldwide


A bigger killer than HIV/AIDS, Parkinson's Disease, emphysema and homicide, in the U.S.


Likelihood of death among individuals with MRSA Versus those infected with MSSA


Projected Annual Worldwide Statistics in 2050

10 Million

Deaths Annually

$100 Trillion

Costs By 2050


Our Technology

Our research platform enables the discovery of novel direct lytic agentsto with activity against specific bacterial pathogens.

Learn More »

Contrafect Corporation

We are focused on developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases.

Learn More »